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Malignant pleural effusions (MPE) are a common clinical problem in patients with
neoplastic disease. The development of MPEs in advanced malignancies can cause
signiﬁcant morbidity and mortality. Predominant symptoms of dyspnea, cough, and chest
discomfort are usually debilitating. Given the poor prognosis of majority of these patients,
palliation is more desirable than cure of an individual complication. Despite multiple new
therapies placement of chest tube with sclerotherapy remains the standard of care. The
purpose of this article is to review the emerging therapeutic options for MPE management.
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Pleural effusions are a common and devastating complica-
tion of advanced malignancies. The annual incidence of
malignant pleural effusions (MPE) in the United States is
estimated to be around 150,000–175,000 cases per year.1,2
MPE signiﬁes incurable disease with considerable morbidity
and mortality. The patients with MPE have a dismal mean
survival of approximately 6 months with an exception of
breast cancer associated MPE.3 In addition, the patient is
often malnourished and debilitated. Untreated, death
usually ensues within a few months due to the primary
disease or to complications related to the effusion.
Malignancies associated with MPE
The most common etiologies for MPE are lung cancer, breast
cancer, lymphoma, ovarian cancer, and gastric cancer, in
order of decreasing frequency.4,5 These account for approxi-
mately 80% of all MPE.4,5 In approximately 7% of patients
with MPE, the primary site of malignancy is unknown at the
time of initial diagnosis (Figure 1).4,5
Pathogenesis of MPE
An MPE is diagnosed when malignant cells are found in
pleural ﬂuid on cytologic examination or on pleural biopsy.
An effusion found in the face of known malignancy but
without any cytologic evidence of malignant cell per see in
the pleural ﬂuid is termed as para-malignant effusion. ThisFigure 1 Malignancies associated witerm implies the secondary relation of the effusion to the
malignancy without a direct extension or involvement.6
Lymphatic obstruction is the predominant cause of para-
malignant effusions.6,7 Other local effects of tumor causing
a para-malignant effusion are airway obstruction, pneumo-
nia, atelectasis, and trapped lung. Effusions can also result
from systemic effects of tumor and adverse effects of
therapy. The lymphatics of parietal pleura play a major role
in the re-absorption of pleural ﬂuid and proteins.8 MPEs are
usually caused by disturbance of the normal Starling forces
regulating absorption of ﬂuid in the pleural space, via
obstruction of mediastinal lymphatics draining the parietal
pleura. Interference in integrity of the lymphatic system
anywhere between parietal pleura and mediastinal lymph
nodes can result in pleural effusion. A strong relationship
has been found between carcinomatous inﬁltration of the
mediastinal lymph nodes and occurrence of MPE.6,7 Tumors
that metastasize frequently to these nodes, i.e. lung cancer,
breast cancer, and lymphoma, cause most malignant
effusions. MPE generally do not develop in sarcomas because
of the characteristic absence of lymphatic metastasis. Other
possible mechanisms leading to MPEs include direct tumor
invasion (in lung cancers, chest wall neoplasms, and breast
carcinoma) and hematogenous spread to parietal pleura.
Local inﬂammatory changes in response to tumor invasion
can cause increased capillary permeability, with resultant
effusions. Molecular mechanisms9,10 of MPE pathogenesis
suggest that, the production of MPE is associated with the
ability of tumor cells to invade the pleura and express high
levels of vascular endothelial growth factor (VEGF) causing
increased vascular permeability.th malignant pleural effusions.4,5
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Malignant pleural ﬂuid pH is usually o7.30. High tumor
burden is associated with lower pH, which is associated with
lower chance of pleurodesis, and poor survival.11 In one
study, patients with mesothelioma with pleural ﬂuid pH
(ppH)47.32 lived a median of 21.2 months (95% conﬁdence
interval (CI) 16.5–30.0 months) after diagnosis compared
with patients who had ppHp7.32 who lived a median of 13.4
months (95% CI 4.5–16.2 months; p ¼ 0.0194).12 Baseline
ppH correlates with survival in epithelial mesothelioma
patients. In a study by Crnjac et al.13 in breast cancer
patients thoracoscopic mechanical pleurodesis (TMP) and
talc pleurodesis (TP) were equally successful (92% and 91%)
in patients with pH levels above 7.3 but in patients with pH
below 7.3 TMP was successful in 81% while TP was effective
in 55% to cause successful pleurodesis. When compared with
nonmalignant pleural effusions, patients with large or
massive MPEs were more likely to have pleural ﬂuids with
higher RBC counts (18.0 10(9) cells/L vs. 2.7 10(9) cells/L,
respectively; po0.001) and lower adenosine deaminase
(ADA) activity (11.5 U/L vs. 31.5 U/L, respectively;
po0.001), higher lactate dehydrogenase levels (641U/L
vs. 409U/L, respectively; p ¼ 0.001), and lower pH (7.39 vs.
7.42, respectively; p ¼ 0.006).14 MPE is also associated with
elevated protein levels. Elevated pleural ﬂuid amylase
levels were suggestive of malignancy in 61% of patients in
one series.15 The most frequent tumor was lung cancer
usually adenocarcinoma of lung. Pleural ﬂuid cytology is the
simplest and most deﬁnitive way to make a diagnosis. In one
series the diagnostic yield from pleural ﬂuid cytology was
62%, while the diagnostic yield of medical thoracoscopy (MT)
approached 95%.16 The diagnostic yield of pleural biopsy for
malignancy varies between 44% and 50%.16,17
Current therapeutic options
MPE restricts ventilation and causes progressive shortness of
breath. Pleural deposits of tumor can cause signiﬁcant
pleuritic pain. Lymphangitic pulmonary metastases further
worsen pulmonary function. With the diagnosis of a MPE,
palliative therapy should always be considered due to poor
prognosis of a vast majority of these patients. A thorough
evaluation of the patient’s symptoms, general health
functional status, and expected survival should be kept in
mind.
In some malignancies, initial response of MPE to che-
motherapy (breast and small cell lung cancer) and radiation
therapy (lymphoma) is quite good. It results in complete
resolution of MPE precluding any further intervention
(Table 1).
Asymptomatic patients with either a malignant or a para-
malignant effusion need not be treated initially. However,
many will subsequently develop progressive, symptoms
requiring therapy (Figure 2).
Therapeutic thoracentesis
The ﬁrst step in the management of MPE is to determine if
the patient has symptomatic beneﬁts from removal of the
pleural ﬂuid. A considerable number (up to 50%) of patientswith malignant effusions may not have signiﬁcant improve-
ment in breathlessness or in exercise tolerance after
thoracentesis,18 due to co morbidity (e.g. emphysema),
general debility from the tumor, or the presence of a
‘‘trapped lung’’. The trapped lung can be due to tumor
encasement of the lung or endobronchial obstruction with
distal atelectasis. In selected patients showing signiﬁcant
improvement in dyspnea on thoracentesis, repeated ther-
apeutic thoracentesis may serve as a primary therapeutic
modality, especially in patients with advanced disease, poor
performance status, limited survival of weeks to months, or
in patients preferring periodic outpatient therapeutic
thoracentesis to hospitalization for invasive and morbid
procedures. The volume of ﬂuid that can be safely removed
from the pleural space during a therapeutic thoracentesis is
unknown. But removal of only 1–1.5 L of ﬂuid at one sitting is
recommended.2
Therapeutic thoracentesis is not reliably effective for
long-term control, as pleural ﬂuid may re-accumulate
rapidly in a symptomatic fashion. In one study, for instance,
symptomatic MPE was noted to recur within an average of
4.2 days after thoracentesis alone.19 Re-expansion pulmon-
ary edema although rare can occur after rapid removal of
pleural ﬂuid from the pleural space. The mechanism of
edema is believed to be increased capillary permeability.
The injury may be related to the mechanical forces causing
vascular stretching during re-expansion20 or to ischemia-
reperfusion injury.
There are no absolute contraindications to performing
thoracentesis. Relative contraindications include a minimal
effusion (less than 1 cm in thickness form the ﬂuid level to
the chest wall on a lateral decubitus view), bleeding
diathesis, anticoagulation,21 and mechanical ventilation.
Important complications of thoracentesis include pneu-
mothorax, bleeding, infection, and spleen or liver lacera-
tion. These complications should be discussed with patients
prior to embarking on a plan of repeated thoracentesis.Chest tube thoracostomy and chemical
pleurodesis
Chest tube thoracostomy and chemical pleurodesis with talc
is the standard of care for the management of MPE in the US
and many countries. Other modalities such as pleural
catheters (PCs) are becoming more common in US and
Canada while medical pleuroscopy is becoming very popular
in Europe.
Chest tube thoracostomy is an inpatient procedure
requiring an average of 5–7 days in the hospital. Generally,
a 28–32 French plastic tube is inserted in the pleural space
under local anesthesia or conscious sedation. Although there
is emerging data on the use of small bore tubes for chemical
pleurodesis. In a recent prospective study by Spiegler
et al.22 small 14 French catheters resulted in chemical
pleurodesis in 79% of patients. (Complete pleurodesis 48%,
partial pleurodesis 31%.) Various chemicals have been used
in an attempt to produce pleurodesis. There is data from
animal studies on the use of transforming growth factor
(TGF) resulting in pleurodesis faster than talc23,24 (Table 2).
Patients selected for pleurodesis should have signiﬁcant
symptoms that are relieved when pleural ﬂuid is evacuated.
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Table 1 Different management options for malignant pleural effusions.
Options Advantages Disadvantages
Observation  Non invasive  Most will progress and require therapy
Repeated
therapeutic
thoracentesis
 Good option for patients with limited life
expectancy
 Prompt relief of dyspnea
 Rapid reaccumilation
 Repeated procedures
 Multiple hospital visits
 Procedure related complications
 Re-expansion pulmonary edema
 Reduced quality of life
Chemical
pleurodesis with
chest tubes
 Highly effective (pleurodesis 81–93%)25–27  Hospitalization 5–7 days
 Expensive
 Invasive
 Associated morbidity
Medical
thoracoscopy and
VATS
 Highly effective (pleurodesis in greater than 90% of
patients)36–39
 Diagnosis and pleurodesis can be performed at the
same time
 Inpatient
 Invasive
 Associated morbidity
 Contraindicated if patient cannot tolerate
single lung ventilation (VATS)
Pleuro-peritoneal
shunts
 Could be an option in patients with failed chemical
pleurodesis
 Shunt malfunction
 Infection
 Requires frequent pumping by the patient
Chronic indwelling
pleural catheters
 Good option for motivated patients
 Inpatient or out patient placement of catheter and
mostly outpatient management of catheter and
drainage
 Minimally invasive
 Cost effective
 Control of dyspnea
 Out patient pleurodesis (42–58%)53,55,57 without
chemicals
 Can be used in patients with trapped lung for
palliation of symptoms
 Catheter can be used to administer intrapleural
anticancer agents
 Family member or a visiting nurse required for
home drainage
 Catheter site Infection
 Low pleurodesis rate compared to chemical
pleurodesis with chest tube or VATS/medical
pleuroscopy
G. Khaleeq, A.I. Musani942There should be evidence of complete re-expansion of the
lung without evidence of bronchial obstruction or trapped
lung. After chest tube placement radiographic conﬁrmation
is obtained to demonstrate complete re-expansion of the
lung with evacuation of the ﬂuid. At this point, intravenous
narcotic analgesics and/or sedation are often recommended
because of the pain associated with many sclerosing agents.
The sclerosing agent of choice is then instilled into the
pleural space via the chest tube, typically in a solution of
50–100 cm3 of sterile saline. The chest tube is then clamped
for 1–2 h, with or without rotation of the patient being
required. The chest tube is then subsequently reconnected
to 20 cmH2O suction. It is then recommended that suction beapplied to the chest tube until the 24-h output from the
chest tube is less than 150mL.
Commonest complications with chemical pleurodesis are
fever and pain.31 Other rare complications include local site
infection, empyema, arrhythmias, cardiac arrest, myocar-
dial infarction, and hypotension. Acute respiratory distress
syndrome (ARDS), acute pneumonitis, and respiratory fail-
ure have also been reported to occur after both talc
poudrage and slurry.31 In a recent multicenter prospective
study of 558 patients with MPEs none of the patients
developed ARDS while using of large-particle talc.32
In a recent review by Tan et al.33 46 randomized control
trials (RCTs) with a total of 2053 patients with MPEs were
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Symptomatic MPE which responds to 
Thoracentesis
No Evidence for 
Trapped Lung
Evidence for 
Trapped Lung present
Tunneled pleural
Tunneled pleural 
catheter
catheter
+ intra-pleural lytics
Medical Thoracoscopy
+/-lytics through  chest
If patient is an 
optimal candidate 
tube
Standard Chest tube
+/-lytics
Medical Thoracoscopy  
with Talc poudrage
Standard Chest tube
with 
Sclerosing Agent
Decortication
If patient is an optimal
candidate
Tunneled pleural catheter
VATSDecortication
+/-Sclerosing Agent
Chest CT
Loculations
Figure 2 Treatment algorithm for MPE.
Table 2 Agents used for chemical pleurodesis.
Chemicals used for pleurodesis Successful pleurodesis
Talc (most commonly used) 81–93%25–27
Tetracycline (doxycycline) 80–85%28–30
Bleomycin 72%28
Emerging paradigms in the management of malignant pleural effusions 943reviewed for effectiveness of pleurodesis. Talc tended to be
associated with fewer recurrences when compared to
bleomycin (RR, 0.64; 95% CI, 0.34–1.20). Tetracycline (or
doxycycline) was not superior to bleomycin (RR, 0.92; 95%
CI, 0.61–1.38). When compared with bedside talc slurry,
thoracoscopic talc insufﬂation was associated with a
reduction in recurrence (RR, 0.21; 95% CI, 0.05–0.93).
Strategies such as rolling the patient after instillation of the
sclerosing agent, protracted drainage of the effusion and
use of larger chest tubes were not found to have any
substantial advantages. Talc appears to be effective and
should be the agent of choice for pleurodesis. Thoracoscopic
talc insufﬂation is associated with fewer recurrences of
effusions compared with bedside talc slurry, but this is based
on two small studies. Where thoracoscopy is unavailable
bedside TP has a high success rate and is the next best
option.
When initial pleurodesis for MPE fails, several alternatives
may be considered. Repeat pleurodesis may be performed
either with instillation of sclerosants through a chest tube orby thoracoscopy and talc poudrage. Repeat thoracentesis
would be the choice for a terminal patient with short
expected survival. Pleuroperitoneal shunting or pleuroect-
omy may be suitable for patients whose clinical condition is
reasonably good and who have experienced pleurodesis
failure. Replacement of the CTwith a small bore indwelling
pleural catheter for indeﬁnite period of time is another
option for terminally ill patients.
Medical thoracoscopy (MT)
With the advent of ﬂexible pleuroscope, MT is becoming a
common procedure performed by pulmonologists around the
world. Simplicity and minimal requirements in terms of
anesthesia and ventilation for this procedure along with high
diagnostic and therapeutic yield makes it preferred proce-
dure in relatively sick patient population.34,35
MT is the visualization of pleural cavity by using non-
disposable ﬂexible instruments. It can be performed under
local anesthesia or conscious sedation, in an endoscopy
suite. There is no need for intubation or single-lung
ventilation.
The pleuroscope
The pleuroscope (model XLTF-240; Olympus; Tokyo, Japan)
is a semi rigid instrument consisting of a handle similar to a
standard ﬂexible bronchoscope. The outer diameter of the
shaft is 7.0mm. The length of the insertion portion is 27 cm,
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bendable distal end (5 cm). The tip is movable in one plane
with the help of a lever on the handle, which is similar to a
conventional ﬂexible bronchoscope. A 2.8-mm single work-
ing channel accommodates the biopsy forceps and other
instruments. Angulation is 1001 and 1301. The instrument
connects to a standard video processor and light source
(models CLV-U40 and CV-240, respectively; Olympus), and
images are viewed on a screen (Figure 3).
Pleuroscopy technique34
The pleuroscopy can be performed using a single-puncture
technique. Patients are placed in the lateral decubitus
position, with the affected side up. Most patients received
IV conscious sedation using midazolam and fentanyl, with
appropriate monitoring. After local anesthesia is placed, a
small incision is made in the mid-axillary line and an 11-mm
trocar is introduced. After all ﬂuid is suctioned, the
pleuroscope is introduced into the pleural cavity, and the
lung, diaphragm, and pleural surfaces are inspected.
Parietal pleural biopsy specimens are obtained when
indicated, and the procedure is followed by talc poudrage
(with 5 g sterilized talc). The procedure is followed by the
placement of a 24F standard chest tube through the trocar.
A chest radiograph is obtained post procedure.
Talc poudrage performed during pleuroscopy has a mean
pleurodesis success rate of greater than 90%.36–39 Various
major and minor complications can occur due to thoracoscopy,
but most are infrequent. The commonest complication is
pneumothorax that occurred in 8.3% of patients in one series36
other common complications included subcutaneous emphy-
sema (5.3%), fever (3.6%) and pain (1.2%). Major complica-
tions such as death, severe sepsis, pulmonary embolism and
hypercapnic coma occurred in 0.6% of patients.36
Experience with MT in MPE management
Kolschmann et al.40 reported 102 patients (45 women, 57
men; 20–83 years of age) who underwent MT and TTP forFigure 3 The pleuroscope (model XLrecurrent MPE between 1999 and 2001. At the end of the
primary observation period of 180 days, 38 of 46 surviving
patients (82.6%) had a successful pleurodesis. Type of
primary neoplasm had no signiﬁcant inﬂuence on success
rate. Adverse effects included empyema in one case and
malignant invasion of the scar. No episode of talc-induced
ARDS was observed.
Ernst et al.41 reported their experience with 34 patients
who were referred for MT between September 2000 and
April 2001. Pleural biopsies were performed in 13 patients,
and TP procedures were performed in 25 patients. Mean
(7S.D.) duration of chest tube drainage was 2.971.8 days
post procedure. There were no complications reported.
Video-assisted thoracic surgery (VATS)
VATS requires general anesthesia and single-lung ventilation.
VATS is contraindicated when the patient cannot tolerate
single-lung ventilation (such as prior contra lateral pneu-
monectomy, or abnormal airway anatomy precluding
placement of double-lumen endotracheal tube), pleural
adhesions precluding the safe insertion of the thoracoscope,
and insufﬁcient expertise to deal with the complications of
the procedure.
VATS technique
In a standard operative approach patients are treated under
general anesthesia and with single-lung ventilation. Proce-
dure is performed in the lateral decubitus position with a
10-mm port in the sixth space of the mid-axillary line and a
5-mm inframammary port. After deﬂation of the lung a
thorough inspection of the pleural cavity is performed and
the effusion is completely evacuated. Where necessary
adhesiolysis is performed to ensure expansion of the
underlying lung.42 Once expansion of the lung has been
established and any remaining ﬂuid drained, 4–5 g of sterile
talc is insufﬂated into the pleural cavity to ensure a general
cover of both surfaces. A 20-Fr intercostal drain is inserted
and directed to the apex and a 28-Fr drain is directed toTF-240; Olympus; Tokyo, Japan).
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Figure 4 (a) Pleural catheter with one way valve at the end,
(b) disposable vacuum bottle with drainage tubing.
Emerging paradigms in the management of malignant pleural effusions 945base, and both are connected to underwater seal drain
bottles.42,43
Experience with VATS in MPE management44,45
In a recent paper by Gasparri et al.,44 analyzed the results of
VATS chemical pleurodesis in patients with recurrent pleural
effusion from breast carcinoma. TP was performed in all
cases, with no intraoperative or postoperative complica-
tions. Median length of hospital stay was 5 days (range, 5–8).
The overall success rate of the surgical procedure was 89%
(CI, 79–95%) with a mean follow-up of 22 months (range,
2–81 months). The overall survival time was 17 months
(range, 2–80).
In summary, TP via VATS is an effective and safe procedure
that yields a high rate of success at the ﬁrst attempt and
achieves long-term control of MPE.45,46 Concomitant biop-
sies can be performed during the VATS procedure and can
play a role in subsequent decision-making. In spite of these
advantages VATS requires general anesthesia with selective
endobronchial intubation and at least three ports of entry
moreover it needs extensive training and is usually
performed by surgeons. In comparison MT can be performed
by pulmonologists in a bronchoscopy suite, is much less
invasive requiring only one port of entry and can be
performed under conscious sedation.
Pleuroperitoneal shunt47,48
The pleuroperitoneal shunts transfer pleural ﬂuid into the
peritoneal cavity when manually pumped. The shunts are
indicated for use in patients with refractory pleural
effusions, either malignant or chylous. This approach can
also be used for patients who cannot achieve pleurodesis
due to trapped lung. Pleuroperitoneal shunting is also a
viable option for symptomatic MPEs that has failed chemical
pleurodesis or cannot undergo surgery. The procedure is safe
and effective in the hands of experienced operators, with
palliation achieved in 80–90% of properly selected patients.
The shunt may be particularly beneﬁcial in refractory
chylothorax, since it allows the recirculation of chyle.
Few complications have been associated with placement
of pleuroperitoneal shunts, and they can be inserted in
patients who are poor surgical candidates. The major
problem has been shunt failure, which is most commonly
due to clotting of the catheter. It is not known whether
patients who have experienced shunt occlusion are at
greater risk for occlusion after a new shunt is placed.
Experience with pleuroperitoneal shunt in MPE
management
Reich et al.47 used 17 Denver pleuroperitoneal shunt in 13
patients from 1991 to 1992. All patients were relieved of
their dyspnea. The average length of patency was 2.5
months, and fewer than 25% of the shunts clotted.
Lee et al.48 published their 2 years experience from 1991
to 1993. Twenty shunts were inserted into 19 patients. All
patients but one was relieved of dyspnea. The mean
duration of patency was 26 months and fewer than 25% of
the shunts clotted before the death of the patient.Indwelling, tunneled PC
The adaptation of small-bore catheters for prolonged
inpatient and outpatient drainage of pleural effusions has
gone through several stages of developments. Dozens of
recent publications on its utility and effectiveness for the
long term management of MPE has led to its popularity
and mainstream use as an alternative to conventional
modalities.49–52
The commercially available indwelling, tunneled pleural
catheter is speciﬁcally designed for managing pleural
effusions and was approved by the United States Food and
Drug Administration in 1997 (Figure 4).Catheter placement
The tunneled pleural catheter is a 66 cm long, 15.5F, silicone
rubber catheter with fenestrations along the distal 24 cm.
A valve at the proximal end of the catheter prevents ﬂuid or
air from traveling along the catheter until the matched
drainage line has accessed it. A polyester cuff helps prevent
infection and secure the catheter in place by inciting
granulation in the subcutaneous tunnel. The placement of
this catheter is very simple and is usually done on an
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units under conscious sedations. The insertion technique is
essentially a combination of thoracentesis and modiﬁed
Seldinger technique. A recent publication in CHEST by
Tremblay and Michaud from Canada describes the technique
in a step-by-step manner,53 after placement, pleural ﬂuid
may be drained periodically from the chest into vacuum
bottles by connecting the drainage line access tip to the
valve.
Subsequent drainages are performed using a special
vacuum bottle system. The bottle has a pre-connected tube
containing a catheter to be inserted into the valve of the PC.
Drainage is usually performed every other day, but can be
done more frequently. A typical drainage takes no more than
15min and is readily accomplished by a visiting nurse, family
members, or the patient. If the patient has three drainages
that are scant (o50 cm3) and imaging shows no ﬂuid
reaccumulation, the pleural catheter is removed as sponta-
neous pleurodesis has occurred.54Experience with the tunneled PCs
In 1999, Putnam et al.55 published his study comparing long
term pleural drainage catheters with doxycycline scler-
otherapy. Equivalent safety and efﬁcacy were shown and
there was no difference in median survival. The PC group
had a trend toward greater improvement in dyspnea after
exercise at 1–3 months but similar improvements were seen
in quality of life. The median hospitalization time was 1 day
for PC patients, and 6.5 days for sclerotherapy patients.
Spontaneous pleurodesis developed in 46% of PC patients
(median 29 days, range 8–223 days), while pleurodesis
occurred in 54% of sclerotherapy patients.
In 2000, Putnam et al.56 looked at PC patients (n ¼ 100;
60 outpatient, 40 inpatient) treated from 1994 to 1998 and
compared with 68 consecutive in-patients treated with
chest tube and sclerosis between 1994 and 1997 at their
institution. Hospital charges were obtained from date of
insertion (day 0) through day 7. He found signiﬁcantly lower
hospital charges for outpatient catheter placement Patients
treated with outpatient PC (n ¼ 60) had early (7-day) mean
charges of $339171753 compared with inpatient PC
(n ¼ 40, $11,18877964) or inpatient chest tube (n ¼ 68,
$783074497, S.D.) (po0.001).
In 2004, in our retrospective analysis of 24 out patients
and 27 PC57 we reported outpatient control of MPEs with
100% relief in dyspnea and spontaneous pleurodesis in 58% of
patients without any added intervention in a mean period of
39 days (range 7–85days).
Complication rates related with PC are low and compare
favorably with those seen with other treatment options. In a
series of 250 patients,53 the commonest complication was
symptomatic loculation occurring in 8% of patients, followed
by unsuccessful insertion and asymptomatic loculation in 4%,
empyema in 3%, pneumothorax in 2% other rare complica-
tions included cellulitis, bleeding, catheter dislodgment,
tumor seeding the catheter site, and pain requiring removal
of catheter.
The experience with PC49–61 is not large but appears to be
quite promising. Advantages include cost-effectiveness,
outpatient control of the effusion, and user-friendlytechnology. Pleurodesis may occur spontaneously in
42–58%53,55,57 of patients, within 4–6 weeks. Chemical
pleurodesis remains an option with Pleural catheters (PCs).
The PC can be used to administer intrapleural anticancer
agents and novel therapies for instance, Gene therapy
vectors for intrapleural malignancies.
Systemic treatment options in MPE
management
Systemic chemotherapy can result in complete or partial
resolution in some malignancies including small cell lung
cancer, lymphoma and breast cancer. In a study by Fujita
et al.62 58% of patients with MPE responded to combination
chemotherapy in a median time of 54 days. Most of patients
in this series had adenocarcinoma. In a series of 14 patients,
Ren et al.63 showed that intrapleural instillation of
staphylococcal super antigen resulted in resolution of MPE
without any clinically important adverse effects. In a phase
II clinical study,64 evaluating the efﬁcacy of pemetrexed
(antifolate) resulted in moderate response rate of 14% in
patients with malignant pleural mesothelioma.
Conclusions
Newer modalities of tunneled pleural catheter and medical
pleuroscopy can offer cost-effective and minimally invasive
options for the management of MPE. In our view, these
options should be considered in the algorithm of MPE
management in all MPE patients.
Disclosures
Ghulam Khaleeq: none.
Ali I. Musani: Member speaker panel, Cardinal Health
(previously, Denver Biomedical Inc).
References
1. Marel M, Zrustova M, Stasny B, et al. The incidence of pleural
effusion in a well-deﬁned region. Epidemiologic study in central
Bohemia. Chest 1993;104:1486–9.
2. Antony VB, Loddenkemper R, Astoul P, et al. Management of
malignant pleural effusions. Am J Respir Crit Care Med
2000;162:1987–2001.
3. Ruckdeschel JC. Management of malignant pleural effusions.
Semin Oncol 1995;22:58–63.
4. Sahn SA. Malignancy metastatic to the pleura. Clin Chest Med
1998;19:351–61.
5. Sahn SA. Pleural diseases related to metastatic malignancies.
Eur Respir J 1997;10:1907–13.
6. Chernow B, Sahn SA. Carcinomatous involvement of the pleura:
an analysis of 96 patients. Am J Med 1977;63:695–702.
7. Meyer PC. Metastatic carcinoma of the pleura. Thorax
1966;21:437–43.
8. Staub NC, et al. Transport through the pleura: physiology of
normal liquid and solute exchange in the pleural space. In:
Chretien J, et al., editors. The pleura in health and disease.
New York: Marcel Decker; 1985.
9. Yano S, Shinohara H, Herbst RS, et al. Production of experi-
mental malignant pleural effusions is dependent on invasion of
the pleura and expression of vascular endothelial growth
ARTICLE IN PRESS
Emerging paradigms in the management of malignant pleural effusions 947factor/vascular permeability factor by human lung cancer cells.
Am J Pathol 2000;157:1893–903.
10. Yano S, Herbst RS, Shinohara H, et al. Treatment for malignant
pleural effusion of human lung adenocarcinoma by inhibition of
vascular endothelial growth factor receptor tyrosine kinase
phosphorylation. Clin Cancer Res 2000;6:957–65.
11. Heffner JE, Nietert PJ, Barbieri C. Pleural ﬂuid pH as a
predictor of survival for patients with malignant pleural
effusions. Chest 2000;117:79–86.
12. Aelony Y, Yao JF, King RR. Prognostic value of pleural ﬂuid pH in
malignant epithelial mesothelioma after talc poudrage. Re-
spiration 2006;73:334–9.
13. Crnjac A, Sok M, Kamenik M. Impact of pleural effusion pH on
the efﬁcacy of thoracoscopic mechanical pleurodesis in patients
with breast carcinoma. Eur J Cardio-Thorac Surg 2004;26:
432–6.
14. Porcel JM, Vives M. Etiology and pleural ﬂuid characteristics of
large and massive effusions. Chest 2003;124:978–83.
15. Villena V, Perez V, Pozo F, et al. Amylase levels in pleural
effusions: a consecutive unselected series of 841 patients.
Chest 2002;121:470–4.
16. Loddenkemper R, Boutin C. Thoracoscopy: present diagnostic
and therapeutic indications. Eur Respir J 1993;6:1544–55.
17. Chakrabarti B, Ryland I, Sheard J, et al. The role of Abrams
percutaneous pleural biopsy in the investigation of exudative
pleural effusions. Chest 2006;129:1549–55.
18. Shinto RA, Stansbury DW, Fischer CE, et al. Does therapeutic
thoracentesis improve the exercise capacity of patients with
pleural effusion? Am Rev Respir Dis 1988;135:A244.
19. Anderson CB, Philpott GW, Ferguson TB. The treatment of
malignant pleural effusions. Cancer 1974;33:916–22.
20. Sprung CL, Loewenherz JW, Baier H, et al. Evidence for
increased permeability in reexpansion pulmonary edema. Am
J Med 1981;71:497.
21. McVay PA, Toy PTCY. Lack of increased bleeding after
paracentesis and thoracentesis in patients with mild coagula-
tion abnormalities. Transfusion 1991;31:164.
22. Spiegler PA, Hurewitz AN, Groth ML. Rapid pleurodesis for
malignant pleural effusions. Chest 2003;23:1895–8.
23. Gary Lee YC, Teixeira LR, Devin CJ, Vaz M, Vargas FS, Thompson
PJ, et al. Transforming growth factor-{beta}2 induces pleurod-
esis signiﬁcantly faster than talc. Am J Respir Crit Care Med
2001;163:640–4.
24. Light RW, Cheng D, Lee YCG, Rogers J, Davidson J, Lane KB. A
single intrapleural injection of transforming growth factor-beta
2 produces an excellent pleurodesis in rabbits. Am J Respir Crit
Care Med 2000;162:98–104.
25. Ferrer J, Montes JF, Villarino MA, Light RW, Garcia-Valero J.
Inﬂuence of particle size on extrapleural talc dissemination
after talc slurry pleurodesis*. Chest 2002;122:1018–27.
26. Paschoalini MDS, Vargas FS, Marchi E, Pereira JR, Jatene FB,
Antonangelo L, et al. Prospective randomized trial of silver
nitrate vs talc slurry in pleurodesis for symptomatic malignant
pleural effusions. Chest 2005;128(2):684–9.
27. Walker-Renard P, Vaughan LM, Sahn SA. Chemical pleurodesis
for malignant pleural effusions. Ann Intern Med 1994;120:56.
28. Patz EF, McAdams HP, Erasmus JJ, et al. Sclerotherapy for
malignant pleural effusions: a prospective randomized trial of
bleomycin vs doxycycline with small-bore catheter drainage.
Chest 1998;113:1305.
29. Heffner JE, Standerfer RJ, Torstveit J, et al. Clinical efﬁcacy of
doxycycline for pleurodesis. Chest 1994;105:1743.
30. Pulsiripunya C, Youngchaiyud P, Pushpakom R, et al. The
efﬁcacy of doxycycline as a pleural sclerosing agent in
malignant pleural effusion: a prospective study. Respirology
1996;1:69.
31. Kennedy L, Sahn SA. Talc pleurodesis for the treatment of
pneumothorax and pleural effusion. Chest 1994;106:1215.32. Julius PJ, Gareth C, Phillippe A, et al. Safety of pleurodesis with
talc poudrage in malignant pleural effusion: a prospective
cohort study. Lancet 2007;369(May):1535–9.
33. Tan C, Sedrakyan A, Browne J, et al. The evidence on the
effectiveness of management for malignant pleural effusion: a
systematic review. Eur J Cardio-Thorac Surg 2006;29:829–38.
34. Rodriguez-Panadero F, Janssen JP, Astoul P. Thoracoscopy:
general overview and place in the diagnosis and management
of pleural effusion. Eur Respir J 2006;28(2):409–22.
35. Tassi GF, Davies RJO, Noppen M. Advanced techniques in
medical thoracoscopy. Eur Respir J 2006;28(5):1051–9.
36. Menzies R, Charbonneau M. Thoracoscopy for the diagnosis of
pleural disease. Ann Intern Med 1991;114:271–6.
37. Harris RJ, Kavuru MS, Mehta AC, et al. The impact of
thoracoscopy on themanagement of pleural disease. Chest
1995;107:845–52.
38. Viallat JR, Rey F, Astoul P, et al. Thoracoscopic talc poudrage
pleurodesis for malignant effusions. A review of 360 cases.
Chest 1996;110:1387–93.
39. Colt HG. Therapeutic thoracoscopy. Clin Chest Med 1998;
19:383–94.
40. Steffen K, Arndt B, Adrian G. Clinical efﬁcacy and safety of
thoracoscopic talc pleurodesis in malignant pleural effusions.
Chest 2005;128:1431–5.
41. Armin E, Craig PH, Felix H, et al. A novel instrument for the
evaluation of the pleural space* an experience in 34 patients.
Chest 2002;122:1530–4.
42. Love D, White D, Kiroff G. Thoracoscopic talc pleurodesis for
malignant pleural effusion. ANZ J Surg 2003;73:19–22.
43. Arapis K, Caliandro R, Stern JB, et al. Thoracoscopic palliative
treatment of malignant pleural effusions: results in 273
patients. Surg Endosc 2006;20:919–23.
44. Gasparri R, Leo F, Veronesi G, et al. Video-assisted management
of malignant pleural effusion in breast carcinoma. Cancer
2006;106:271–6.
45. Trotter D, Aly A, Siu L, et al. Video-assisted thoracoscopic
[VATS] pleurodesis for malignant effusion: an Australian teach-
ing hospital’s experience. Heart, Lung Circ 2005;14:93–7.
46. Marrazzo A, Noto A, Casa L, et al. Video-thoracoscopic surgical
pleurodesis in the management of malignant pleural effusion:
the importance of an early intervention. J Pain Symptom
Manage 2005;30:75–9.
47. Reich H, Beattie EJ, Harvey JC. Pleuroperitoneal shunt for
malignant pleural effusions: a one-year experience. Semin Surg
Oncol 1993;9:160–2.
48. Lee KA, Harvey JC, Reich H, et al. Management of malignant
pleural effusions with pleuroperitoneal shunting. J Am Coll Surg
1994;178:586–8.
49. Leff RS, Eisenberg B, Baisden CE, et al. Drainage of recurrent
pleural effusion via an implanted port and intrapleural
catheter. Ann Intern Med 1986;104:208–9.
50. Van Le L, Parker LA, DeMars LR, et al. Pleural effusions:
outpatient management with pigtail catheter chest tubes.
Gynecol Oncol 1994;54:215–7.
51. Zeldin DC, Rodriguez RM. Management of refractory malignant
pleural effusions with a chronic indwelling pleural catheter.
Chest 1991;100:87S.
52. Grodzin CJ, Balk RA. Indwelling small pleural catheter needle
thoracentesis in the management of large pleural effusions.
Chest 1997;111:981–8.
53. Tremblay A, Michaud G. Single-center experience with 250
tunnelled pleural catheter insertions for malignant pleural
effusion. Chest 2006;129:362–8.
54. Hewitt JB, Janssen WR. A management strategy for malignancy-
induced pleural effusion: long-term thoracostomy drainage.
Oncol Nurs Forum 1987;14:17–22.
55. Putnam Jr JB, Light RW, Rodriguez RM, et al. A randomized
comparison of indwelling pleural catheter and doxycycline
ARTICLE IN PRESS
G. Khaleeq, A.I. Musani948pleurodesis in the management of malignant pleural effusions.
Cancer 1999;86:1992–9.
56. Putnam Jr JB, Walsh GL, Swisher SG, et al. Outpatient
management of malignant pleural effusion by a chronic
indwelling pleural catheter. Ann Thorac Surg 2000;69:369–75.
57. Musani AI, Haas AR, Seijo L, et al. Outpatient management of
malignant pleural effusions with small-bore, tunneled pleural
catheters. Respiration 2004;71:559–66.
58. Hewitt JB, Janssen WR. A management strategy for malignancy-
induced pleural effusion: long-term thoracostomy drainage.
Oncol Nurs Forum 1987;14:17–22.
59. Robinson RD, Fullerton DA, Albert JD, et al. Use of pleural
Tenckhoff catheter to palliate malignant pleural effusion. Ann
Thorac Surg 1994;57:286–8.
60. Pollak JS. Malignant pleural effusions: treatment with tunneled
long-term drainage catheters. Curr Opin Pulm Med 2002;8:302–7.61. Pollak JS, Burdge CM, Rosenblatt M, et al. Treatment of
malignant pleural effusions with tunneled long-term drainage
catheters. J Vasc Interv Radiol 2001;12:201–8.
62. Fujita A, Takabatake H, Tagaki S, Sekine K. Combination
chemotherapy in patients with malignant pleural effusions
from non-small cell lung cancer: cisplatin, ifosfamide, and
irinotecan with recombinant human granulocyte colony-stimu-
lating factor support. Chest 2001;119(2):340–3.
63. Ren S, Terman D, Bohach G, Silvers A, Hansen C, Colt H, et al.
Intrapleural staphylococcal superantigen induces resolution of
malignant pleural effusions and a survival beneﬁt in non-small
cell lung cancer. Chest 2004;126(5):1529–39.
64. Scagliotti GV, Shin DM, Kindler HL, et al. Phase II study of
pemetrexed with and without folic acid and vitamin B12 as
front-line therapy in malignant pleural mesothelioma. J Clin
Oncol 2003;21:1556.
